ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-25. Check what remains unresolved below before relying on it.
What does this change in the investment case for ADARx Pharmaceuticals?
Upsized biotech issuance injects $446.3M into clinical siRNA pipeline funding, providing a fresh pricing benchmark for late-stage biotech IPO demand.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share. |
| What else was confirmed? | Reported factGross proceeds from the upsized offering total approximately $446.3 million. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for ADRX yet — this is the next research task. |
| What would change the assessment? | UnknownADRX Nasdaq Market Open — Opening trade prints and intraday volume vs. $17 offering price. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · ADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share.
- · Gross proceeds from the upsized offering total approximately $446.3 million.
- · Shares will commence trading on Nasdaq under the ticker ADRX on September 25, 2026.
Public research record
Research framework · page evidenceCompleted event assessment
nasdaq public listing and capital raise liquidity
| Type | Claim | Scope |
|---|---|---|
| Assumption | ADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17.00 per share. | 2026-09-25 |
| Interpretation | nasdaq public listing and capital raise liquidity | ADRX |
Countercase, invalidators, and sources
First-day trading exhibits strong secondary performance, reinforcing health of healthcare ECM issuance.
- · ADRX Nasdaq Market Open — Opening trade prints and intraday volume vs. $17 offering price.
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering · 2026-09-24
What remains unresolved
- Base path
- Shares trade near issue price as broader equity market volatility absorbs liquidity.
- Adverse path
- Macro rate pressure dampens speculative appetite, pushing debut below offering price.
- Supportive path
- First-day trading exhibits strong secondary performance, reinforcing health of healthcare ECM issuance.
- · ADRX Nasdaq Market Open — Opening trade prints and intraday volume vs. $17 offering price.today
Evidence
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering2026-09-24
“ADARx Pharmaceuticals... priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026.”
Supports: ADARx priced upsized $446.3M IPO at $17 per share to trade on Nasdaq under ADRX on September 25, 2026.